Importance of virological response in the early stage of telaprevir-based triple therapy for hepatitis C

Figure 1 Transition of the virological response rate by sustained virological response status. The virological response (VR) rates were significantly higher in the sustained VR (SVR) than the non-SVR group between weeks 2 and 8 (26.9% vs 0.0%, 59.8% vs 25.6%, 81.6% vs 35.0%, 98.5% vs 65.0% and 98.5% vs 86.5% at weeks 2, 3, 4, 6 and 8, respectively. P < 0.0001 at weeks 2, 3, 4 and 6. P = 0.0027 at week 8), although there was no statistical difference at week 1 or 12 (7.3% vs 0.0% and 100% vs 97.3%, respectively). ^aP < 0.01, ^bP < 0.0001, vs SVR group.